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Pharmacological treatment for atrial ﬁbrillation has a variety of purposes, such as
pharmacological deﬁbrillation, maintenance of sinus rhythm, heart rate control to prevent
congestive heart failure and prevention of both cerebral infarction and atrial remodeling.
Sodium channel blockers are superior to potassium channel blockers for atrial deﬁbrillation,
while both sodium and potassium channel blockers are eﬀective in the maintenance of sinus
rhythm. In general, digitalis or Ca antagonists are used to control heart rate during atrial
ﬁbrillation to prevent congestive heart failure, while amiodarone or bepridil also reduce heart
rates during atrial ﬁbrillation. Anticoagulant therapy with warfarin is recommended to prevent
cerebral infarction and angiotensin converting enzyme antagonists or angiotensin II receptor
blockers are also used to prevent atrial remodeling. One should select appropriate drugs for
treatment of atrial ﬁbrillation according to the patient’s condition.
(J Arrhythmia 2005; 21: 358–371)
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Introduction
Pharmacological treatment for atrial ﬁbrillation
encompasses various topics including deﬁbrillation
by antiarrhythmic agents, maintenance of sinus
rhythm with antiarrhythmic agents, rate control
during atrial ﬁbrillation by suppression of atrioven-
tricular nodal conduction for prevention of heart
failure, and anticoagulant therapy to prevent throm-
boembolism. Furthermore, patients with decreased
cardiac functions and certain patients suﬀering from
recurrent atrial ﬁbrillation have been extensively
treated with angiotensin converting enzyme (ACE)
inhibitors or angiotensin II receptor blockers (ARB)
to prevent congestive heart failure and occurrence of
atrial remodeling attributable to atrial ﬁbrillation,1–4)
indicating signiﬁcant multiplicity of drugs to be used
for diﬀerent types of atrial ﬁbrillation. Accordingly,
there has been a controversial issue regarding
whether any guidelines for treatment of atrial
ﬁbrillation developed in Europe and America,5) or
the results obtained in comparative studies on rate
controls and rhythm controls,6–8) could be incorpo-
rated into the existing Japanese guidelines for atrial
ﬁbrillation.9) The present article is a review of drug
therapies for atrial ﬁbrillation in Japan.
Indication of drug therapies for treat-
ment of atrial ﬁbrillation
For deciding the therapeutic strategy for atrial
ﬁbrillation, classiﬁcation of atrial ﬁbrillation accord-
ing to its pathophysiology plays a useful role. For the
beneﬁts of eﬀective classiﬁcation leading to practical
therapeutic strategy, atrial ﬁbrillation can be classi-
ﬁed as follows: transient atrial ﬁbrillation induced by
ingestion of alcoholic beverages, inadequate sleep
and overwork; paroxysmal atrial ﬁbrillation with
recurrence and spontaneous termination; persistent
atrial ﬁbrillation characteristic of no spontaneous
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termination but being responsive to deﬁbrillation;
and permanent atrial ﬁbrillation characterized by the
absence of spontaneous termination and failure to
deﬁbrillate and the planning of further attempts to
restore sinus rhythm.10) Customarily, chronic atrial
ﬁbrillation has been deﬁned as permanent atrial
ﬁbrillation combined with a part of persistent atrial
ﬁbrillation which is left untreated with deﬁbrillation.
This classiﬁcation is directly correlated with the
intervention for atrial ﬁbrillation, suggesting that
transient atrial ﬁbrillation can be prevented by
elimination of the inducing factors. In principle, it
is advocated to try deﬁbrillation at ﬁrst for treatment
of either paroxysmal or persistent atrial ﬁbrillation,
while in patients presenting with recurrence within a
short period of time despite reaching sinus rhythm
antiarrhythmic drug therapy is required to maintain
sinus rhythm. For the treatment of patients with
persistent atrial ﬁbrillation and with long-lasting
permanent atrial ﬁbrillation, rate control for preven-
tion of heart failure, and anticoagulant therapies for
prevention of thromboembolism occupy a major
position.
Once atrial ﬁbrillation occurs, the atrium is
irregularly excited at the frequency of 450–600 per
minute and its excitation wave is conducted in a
disorder by manner through the atrioventricular
node, certainly resulting in irregular ventricular
excitation. This is the reason why atrial ﬁbrillation
is termed as absolute arrhythmia. With the atrioven-
tricular node possessing good conductibility, the
ventricular response increases in number, evolving
to irregular tachycardia. Due to these features, the
patients perceive signiﬁcant palpitation and abnor-
mal sensation around their chests when atrial
ﬁbrillation initiates. These symptoms derive from
pulse irregularity and tachycardia. Despite the
presence of pulse irregularity, suppression of tachy-
cardia successfully leads to disappearance of sub-
jective symptoms. These experiences imply that
inhibition of atrioventricular nodal conduction is
eﬀective. On the other hand, among the patients with
atrial ﬁbrillation admitted to the intensive care unit
(ICU), improvement of cardiac functions by treat-
ment of underlying heart diseases is associated with
disappearance of atrial ﬁbrillation; on the other hand,
aggravation of underlying heart diseases is some-
times accompanied with onset of atrial ﬁbrillation.
As a natural consequence, pharmacological treat-
ments should be decided by not only focusing one’s
attention on atrial ﬁbrillation itself but also consid-
ering alleviation of systemic conditions. To realize
these objectives, ACE inhibitors1,2) and ARB3,4) have
been used clinically.
Irrespective of paroxysmal atrial ﬁbrillation or
permanent atrial ﬁbrillation (chronic atrial ﬁbrilla-
tion), there is no signiﬁcant diﬀerence in incidence
of cerebral infarction.11) Accordingly, prophylaxis of
thromboembolism is a useful therapeutic remedy to
be applied to any type of atrial ﬁbrillation.
Pharmacological deﬁbrillation
For the purpose of selecting the eﬀective antiar-
rhythmic agents for the treatment of deﬁbrillation,
comparison was made between sodium (Na) channel
blockers and potassium (K) channel blockers
(Figure 1, 2), indicating that Na channel blockers
exhibited deﬁnitely superior deﬁbrillation ef-
fects.12–15) Accordingly, we can conclude that Na
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Figure 1 Cumulative percentage of con-
version of atrial ﬁbrillation to sinus rhythm
from ﬁrst trial dose with trial medication or
spontaneously after randomization (1 patient
in sotalol group): quinidine as Na channel
blocker, and sotalol as K channel blocker.
(Represented with permission from reference
14)
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channel blockers are the ﬁrst-line therapy for
deﬁbrillation of atrial ﬁbrillation, with K channel
blockers being recognized as the second-line ther-
apy. In Japan, currently available are 9 diﬀerent
kinds of Na channel blockers which can be used for
deﬁbrillation of atrial ﬁbrillation (Table 1). On
deﬁbrillation, we have to make proper selection of
either intravenous or oral administration of antiar-
rhythmic agents according to the situation and
condition of the patient. Intravenous administration
is mainly used for deﬁbrillation because of the rapid
appearance of the drug’s eﬀect; in contrast, however,
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Figure 2 Reversion to sinus rhythm at 120
minutes.
Mean time to reversion (SD): ﬂecainide
24 15 minutes, amiodarone 56 38 mi-
nutes, and placebo 49 44 minutes. (Repre-
sented with permission from reference 13)
Table 1 Characteristics of antiarrhythmic agents to be used for treatment of atrial ﬁbrillation.
AAD LV function Excretion (%) Proarrhythmic factor Non-cardiac adverse effects
procainamide # kidney (60), liver (40) QT prolong, QRS widen SLE, agranulocytosis, liver damage
disopyramide # kidney (70) QT prolong, QRS widen thirsty, retention of urine, hypoglycemia
quinidine ! liver (80), kidney (20) QT prolong, QRS widen cinchonism (dizziness), GI symptom
propafenone # liver QRS widen muscle pain, headache, nausea, liver damage
aprindine ! liver QRS widen (QT prolong) numbness, tremor, liver damage, leucocytosis
cibenzoline # kidney (80) QRS widen headache, thirsty, retention of urine,
hypoglycemia
pirmenol # kidney (70) QT prolong, QRS widen headache, thirsty, retention of urine
ﬂecainide # kidney (85) QRS widen dizziness, tinnitus, photophobia, diarrhea
pilsicainide #! kidney QRS widen GI symptom, central nervous system
symptom (a few)
bepridil ! kidney (50) QT prolong, bradycardia dizziness, headache, constipation, malaise
verapamil # liver (80), kidney (20) bradycardia constipation, headache, ﬂashing
diltiazem # liver (60), kidney (35) bradycardia GI symptom, ﬂashing
sotalol # kidney (75) QT prolong, bradycardia asthma, headache, malaise
amiodarone ! liver QT prolong, bradycardia lung ﬁbrosis, thyroid damages, corneal
microdeposits
nifekalant ! kidney (50), liver (50) QT prolong thirsty, ﬂashing, headache
-blocker # liver, kidney bradycardia asthma, hypoglycemia, weakness,
Raynoud phenomenon
digoxin " kidney Digitalis intoxication loss of appetite, vomiting
The description order of antiarrhythmic agents follow the Sicilian Gambit (Japanese version represented in Circ J 2004; 68 (Suppl IV):
981–1078).
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oral medication of antiarrhythmic agents is preferred
when deﬁbrillation is not urgently required.
1) Intravenous administration of antiarrhythmic
agents
As for intravenous injection, antiarrhythmic
agents currently available for deﬁbrillation in Japan
include procainamide, disopyramide, cibenzoline,
aprindine, ﬂecainide and pilsicainide. Most of these
antiarrhythmic agents exert deﬁbrillation eﬀect at
the levels of 50–70%, except for aprindine which
demonstrates weaker deﬁbrillation eﬀect following
its injection at the usual dose of 100mg. Selection of
the drugs shall be made by referring to the cardiac
functions, as well as the hepatic and renal functions
of the patients.
If patients with signiﬁcant subjective symptoms
but without any lowered cardiac function must be
promptly deﬁbrillated with antiarrhythmic agents,
either of the following Na channel blockers is
intravenously injected: pilsicainide 50–100mg/more
than 5min., ﬂecainide 50–100mg/more than 5min.,
disopyramide 100mg/more than 5min., cibenzoline
70–140mg/more than 5min., procainamide 600–
1000mg/more than 5min., or aprindin 100mg/
10min. When intravenous injection of antiarrhyth-
mic agents is selected for deﬁbrillation, care should
be exercised to administer one intravenous injection
of one drug at least within one hour even though the
cardiac functions are normal.
Even in lone paroxysmal atrial ﬁbrillation, persis-
tence of atrial ﬁbrillation with rapid heart rate
occasionally evolves into a condition characteristic
of heart failure, known as tachycardia-induced
cardiomyopathy.16) It is well documented that ad-
ministration of antiarrhythmic agents under the
condition with heart failure not only aggravates
hemodynamics but also provokes arrythmogenic
eﬀects. As a natural consequence, unless decrease
of heart rates could improve heart failure, direct
current electrical cardioversion should be performed.
If electrical cardioversion fails to restore sinus
rhythm, aprindin at a dose of 100mg is intravenously
infused over 10 minutes, followed by re-deﬁbrilla-
tion. According to the past experiences, this method
oﬀers a signiﬁcantly greater precision of deﬁbrilla-
tion.17) However, prior to electrical cardioversion
intravenous anesthesia is indispensable; therefore,
when this pretreatment is rejected by the patient, all
we have to do is to select antiarrhythmic agents with
less suppression of cardiac functions (Table 1). In
particular, nifekalant, a novel K channel blocker,
possesses little suppressive eﬀect for cardiac func-
tions, thereby being only intravenously administered
as a K channel blocker. The National Health
Insurance System does not cover the payment for
deﬁbrillation of atrial ﬁbrillation; however, it was
reported that nifekalant was eﬀective in deﬁbrillation
of atrial ﬂutter and ﬁbrillation accompanied with
lowered cardiac functions.18) For deﬁbrillation of
atrial ﬁbrillation, nifekalant at a dose of 0.3mg/kg/
5min. should be intravenously injected. Electro-
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Figure 3 Time course of conversion to
sinus rhythm with pilsicainide and placebo.
The ordinate indicates the cumulative con-
version rate and the abscissa represents time
after a single oral administration of the drug.
P < 0:05, yP < 0:01 (Represented with per-
mission from reference 19)
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cardiographic monitoring is indispensable through-
out intravenous administration, besides precautions
being taken to prevent QT prolongation during
injection. In the meantime, we have experience with
deﬁbrillation over time by lowering the ventricular
response rate in the patients with decreased cardiac
functions due to atrial ﬁbrillation with rapid heart
rate. For this purpose, digoxin 0.25mg was intra-
venously infused over 10–20 minutes, resulting in
reduction of heart rates, thereby eventually restoring
sinus rhythm. To the patients with renal dysfunction,
the antiarrhythmic agents highly metabolized in the
liver should be selected. Aprindin and procainamide
represent such agents. If the patients suﬀer from
hepatic dysfunction, antiarrhythmic agents excreted
through kidneys should be selected. Such agents are
represented by disopyramide, cibenzoline, ﬂecainide
and pilsicainide.
2) Oral administration of antiarrhythmic agents
As noted above, oral administration of antiar-
rhythmic agents is usually applied when adequate
time is available. When short-acting agents like
pilsicainide are administered as a single dose
medication at higher doses like 1.5–2-fold doses of
the usual single dose, they exert stronger deﬁbrilla-
tion eﬀects but there is a concern about occurrence
of severe adverse reactions in the aged patient. A
cooperative multicenter randomized placebo control
study (Figure 3) revealed that the deﬁbrillation ratio
by pilsicainide accounted for 45% until 90 minutes
after administration.19) In some cases, administration
of class Ic antiarrhythmic agents evolved atrial
ﬁbrillation into atrial ﬂutter without restoring to
sinus rhythm.
In the patients with lowered cardiac functions,
electrical cardioversion should be selected as the
ﬁrst-line method to deﬁbrillate. However, if medi-
Pharmacological defibrillation
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Figure 4 Selection of Na channel blocker for deﬁbrillation of atrial ﬁbrillation.
(Reproduced with permission from reference 20).
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cation with antiarrhythmic agents is indispensable,
we have to avoid using class Ic antiarrhythmic drugs
(ﬂecainide, propafenone, pilsicainide and cibenzo-
line) possessing stronger Na channel blocking
eﬀects, as well as disopyramide characteristic of
exerting suppression of cardiac functions20)
(Figure 4). In these patients, amiodarone 200mg/
day or bepridil 200mg/day which show K channel
blocking eﬀects will be selected.21) In this connec-
tion, it should be noted that amiodarone and bepridil
exhibit their antiarrhythmic eﬀects 1–2 weeks after
beginning of administration. Particularly in patients
treated with bepridil, deﬁbrillation usually occurs
within 1–2 months (Figure 5). Nakazato22) reported
that bepridil showed favorable conversion eﬀects in
patients with persistent atrial ﬁbrillation. Further-
more, when amiodarone or bepridil are given during
atrial ﬁbrillation with rapid heart rate, it should be
recognized that heart rates are decreased about 2
weeks later, resulting in alleviation of both sub-
jective symptoms and heart failure.
Adverse reactions to be noted are aggravation of
hemodynamics and arrythmogenic eﬀects in the
patients with lower cardiac functions. So as to
prevent onset of arrhythmogenic eﬀects, all we have
to do is to record the electrocardiogram repeatedly
and to pay attention to QT prolongation following
administration of antiarrhythmic agents with K
channel blocking eﬀects, besides giving attention
to prolongation of QRS width after medication with
antiarrhythmic agents with stronger Na channel
blocking eﬀects (Table 1).
Maintenance of sinus rhythm by anti-
arrhythmic agents
It is well known that irregular heart rates are
increased immediately after occurrence of atrial
ﬁbrillation. Persistence of this situation is associated
with suppression of cardiac functions, leading to
persistent atrial ﬁbrillation with heart rates of more
than 130/minute and ﬁnally evolving to heart
failure.16) Nevertheless, this heart failure-like con-
dition is reversible; conversion of atrial ﬁbrillation to
sinus rhythm permits tapering of this undesirable
condition to attain improvement of cardiac function.
initiation 14 days 28 days 42 days
I
II
III
aVR
aVL
aVF
Figure 5 Restoration to sinus rhythm by bepridil.
Atrial excitation wave gradually became bigger after commencement of bepridil administration but converted to sinus rhythm 42
days later.
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Therefore, as heart failure preceeds atrial ﬁbrillation
we reach the conclusion that atrial ﬁbrillation should
be prevented to the greatest possible extent.
It has also been pointed out that atrial ﬁbrillation
persisting over 48 hours facilitates formation of
thrombus in the left atrium and left atrial append-
age.23) Reduction of atrial contractility compared
with that under sinus rhythm is responsible for
thrombus formation. Transesophageal echocardiog-
raphy disclosed higher incidences of spontaneous
echo contrast during atrial ﬁbrillation compared with
those during sinus rhythm. Spontaneous echo con-
trast implies blood ﬂow reduction in the left atrium
which is considered to be a facilitating factor to
induce thrombus formation. The patients with atrial
ﬁbrillation are vulnerable to develop cerebral embo-
lism because of transfer of the isolated thrombus in
left atrium. Moreover, deﬁbrillation of persistent
atrial ﬁbrillation is associated with subsequent left
atrium stunning, leading to thrombus formation in
the left atrium following deﬁbrillation.24) Cardio-
genic cerebral embolism induces extensive cerebral
infarction characteristic of hemorrhagic features,
thereby being intractable to treatment. In any event,
the prevalence of cerebral embolism is 5-fold higher
in patients with atrial ﬁbrillation compared with
those with sinus rhythm.25) Therefore, maintenance
of sinus rhythm plays an essential role in prevention
of these events. Indeed, Komatsu26) reported that
long-term prognosis of patients with paroxysmal
atrial ﬁbrillation varies with the response to antiar-
rhythmic drug therapy. When sinus rhythm is
maintained, the prognosis is good even without
anticoagulation therapy.
When the atrium is experimentally excited by
frequent stimulation, the incidence of subsequent
atrial ﬁbrillation is increased, leading to prolongation
of the persistent period of atrial ﬁbrillation.27)
Furthermore, incidence of atrial excitation during
atrial ﬁbrillation is incrementally increased. Allesie
et al.28) called this phenomenon of susceptibility to
occurrence of atrial ﬁbrillation as electrical remod-
eling. Electrical remodeling bears its fundamental
features such as shortening of eﬀective refractory
period of atrium and change of adaptation of the
atrial refractory period in heart rate, all of which are
assumed to be due to overload of Ca2þ ions induced
by frequent atrial excitation. In parallel with progress
of electrical remodeling, structural remodeling is
also present, whereby together they are called atrial
remodeling due to atrial ﬁbrillation. Given the
structural remodeling formation, it is conceivable
that prompt restoration to sinus rhythm and preven-
tion of recurrence are really important. Since main-
tenance of sinus rhythm even in the ICU is important
after deﬁbrillation, oral antiarrhythmic agents are
used for this purpose. For patients under tracheal
intubation, powdered antiarrhythmic drugs are fre-
quently administered by oral tube.
According to the meta analysis of 8 reports so far
documented on prevention of atrial ﬁbrillation after
deﬁbrillation, it was revealed that the maintenance
ratio of sinus rhythm 3 months and 12 months after
deﬁbrillation with quinidine (70% and 50%) was
signiﬁcantly lower (P < 0:0001) than those of
amiodarone (72.6% and 59.8%) while following
administration of ﬂecainide, the corresponding ratio
(48.5% and 34%) was signiﬁcantly much more lower
than those of quinidine.29) Similar comparison of the
recurrence ratio of atrial ﬁbrillation over an average
of 16 months among amiodarone, sotalol or prop-
afenone disclosed that the recurrent ratio of amio-
darone accounted for 35%, with the counterparts of
sotalol and propafenone being 63% (P < 0:001),
indicating a higher maintenance eﬀect of sinus
rhythm with administration of amiodarone.30) In the
patients with chronic heart failure characteristic of
presenting higher complication ratio with atrial
ﬁbrillation, the reduction ratio of heart rate during
atrial ﬁbrillation following administration of amio-
darone accounted for 20% 2 weeks later and 14%
even 12 months later, indicating a higher ratio
relative to that with placebo (P ¼ 0:006) while the
recovery ratio from atrial ﬁbrillation to sinus rhythm
was 31% and 8% (P ¼ 0:002), with the transition
ratio from sinus rhythm to atrial ﬁbrillation being
4.1% and 8.3%, respectively (P ¼ 0:005), suggesting
the eﬀectiveness of amiodarone.21) These ﬁndings
clearly indicate that the eﬃcacy of K channel
blockers is high in maintenance of sinus rhythm
during lowered cardiac functions. As a natural
consequence, the ﬁrst-line therapy is Na channel
blockers for deﬁbrillation of atrial ﬁbrillation and K
channel blockers exert higher eﬃcacy for mainte-
nance of sinus rhythm. However, it is evident that
the shorter the observation period the higher the
prophylactic eﬃcacy, and with higher dosage the
preventive eﬀect is also higher. In clinical situations,
it is diﬃcult to achieve complete suppression of
atrial ﬁbrillation over a longer period, whereby
selection of antiarrhythmic agents and titration of
doses should be independently decided according to
the patient’s condition.
In these clinical studies on prevention of atrial
ﬁbrillation, comparison was made on the number of
recurrent cases of atrial ﬁbrillation to investigate the
eﬃcacy of antiarrhythmic agents. However, even if
atrial ﬁbrillation recurs, treatment with the antiar-
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rhythmic agent was judged somewhat eﬀective
provided that the persistent period was obviously
shortened or subjective symptoms were alleviated
due to remarkable decrease in the incidences; there-
fore, treatment with the antiarrhythmic agent was
usually continued. Considering these points, we
compared eﬃcacy of several antiarrhythmic agents
which are currently used in Japan. In 60 patients of
63 years of average age presenting with paroxysmal
atrial ﬁbrillation, the eﬃcacy ratios of pilsicainide,
cibenzoline, pirmenol, and bepridil were assessed
during the average observation period of 788 898
days. In Figure 6, the results obtained disclosed that
the eﬃcacy ratios accounted for 57% with pilsicai-
nide, 31% with cibenzoline, 33% with pirmenol and
73% with bepridil.31) In Japan, K channel blockers
are less frequently used for prevention of atrial
ﬁbrillation because the coverage of the National
Health Insurance System price for amiodarone is
limited to use in patients with atrial ﬁbrillation
accompanied by hypertrophic cardiomyopathy.
However, based on clinical results in Europe and
America,12–15,21,29,30) application of K channel block-
ers is gradually increasing to include patients suﬀer-
ing from intractable atrial ﬁbrillation. Considering
this background, the enrolled patients were still
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limited but we compared preventive eﬀects of some
antiarrhythmic agents possessing strong K channel
blocking eﬀects in intractable patients. If intractable
patients are deﬁned as those unresponsive to more
than 3 kinds of antiarrhythmic agents, the ratios of
intractable patients accounted for 50% with amio-
darone, 40% with sotalol and 51% with bepridil32)
(Figure 7), deserving administration of K channel
blockers to the nonresponders to Na channel block-
ers.
On selection of antiarrhythmic agents with the
objective for deﬁbrillation and maintenance of sinus
rhythm, further consideration on the patient’s con-
ditions is required. In principle, antiarrhythmic drugs
which were proved to be eﬀective in deﬁbrillation
should be attempted for maintenance of sinus
rhythm, whereby we have sometimes experienced
that antiarrhythmic agents like aprindine and amio-
darone indicative of lower deﬁbrillation eﬃciency
are eﬀective in prevention of relapse. The factors for
selection of antiarrhythmic drugs to prevent atrial
ﬁbrillation are as follows.
1) Non-elderly patients without underlying dis-
eases: They can be treated with any antiar-
rhythmic agents including Ic class antiarrhyth-
mic drugs characteristic of exerting eﬀective
deﬁbrillation and maintenance of sinus rhythm.
Any antiarrhythmic agents to which attending
physicians are accustomed are acceptable.
Mainly selected for this purpose are pilsicai-
nide, ﬂecainide, cibenzoline, disopyramide,
pirmenol, quinidine, bepridil, propafenone,
and aprindine.
2) Patients with lowered left ventricular functions
(patients with heart failure): Aprindine and
amiodarone which exhibit less suppression of
cardiac function are selected. The Japanese
guidelines20) indicate the selection of antiar-
rhythmic agents depends on cardiac function
(Figure 8).
3) Patients with renal dysfunction: As ﬁrst-choice
drugs, quinidine, aprindine and amiodarone are
to be selected because these antiarrhythmic
agents are chieﬂy metabolized in the liver.
4) Patients with hepatic dysfunction: As ﬁrst-line
drugs, pilsicainide, pirmenol and disopyramide
are selected as these antiarrhythmic agents
which are excreted through the kidneys.
5) Patients whose atrial ﬁbrillation occurs due to
physical work or psychological tension: Usu-
ally  blockers are selected while propafenone
possessing weak  blocking eﬀects is also
selected.
6) Patients whose atrial ﬁbrillation occurs at night
or while resting: Disopyramide, pirmenol and
cibenzoline are selected because of their anti-
cholinergic eﬀects.
7) Patients resistant to multiple drugs: Bepridil or
amiodarone and sotalol are considered for use.
If during the course of maintenance of sinus
rhythm, atrial ﬁbrillation recurs irrespective of treat-
ment with K channel blockers or combination
therapy of K channel blockers and Na channel
blockers, rate control should be considered.
Control of heart rates
Repeated paroxysmal atrial ﬁbrillation is associ-
ated with increase of incidence as well as longer
duration. Subsequently, it evolves into persistent
atrial ﬁbrillation which cannot be spontaneously
terminated, leading to atrial ﬁbrillation resistant to
deﬁbrillation. This progression represents the natural
course of atrial ﬁbrillation frequently encountered in
clinical situations. During such a course, atrial
ﬁbrillation of more than 130/minute frequently
occurs at onset and long-lasting persistence of atrial
ﬁbrillation with rapid heart rate associated with
elevation of the left ventricular end-diastolic pres-
sure results in presentation of congestive heart
failure.16) In order to prevent this progression, rate
control to reduce the heart rate down to 80–100/
minute is required. Given the fact that both pre-
vention of atrial ﬁbrillation and maintenance of sinus
rhythm play an important role in averting occurrence
of complications, however, long-term administration
of antiarrhythmic agents is needed to maintain sinus
rhythm. Antiarrhythmic agents possess suppressive
eﬀects of cardiac function, arrhythmogenic eﬀects
and non-cardiac adverse reactions despite their
variation in potency (Table 1). The CAST study
found that arrhythmogenic eﬀects of antiarrhythmic
agents contributed to occurrence of lethal arrhyth-
mia, whereby the prognosis in the medicated patients
was worse than those in the non medicated patients
with antiarrhythmic agents.33,34) Coupled with these
ﬁndings, it is of interest to note that maintenance of
100% sinus rhythm is rather diﬃcult to achieve by
administration of antiarrhythmic agents;35) therefore,
it is advocated that rate controls without medication
clinically outweighs the pharmacological treatment
in terms of prevention of heart failure. Indeed, three
studies, PIAF,6) AFFIRM,7) and RACE,8) found that
rate control is not worse than rhythm control in
regard to mortality.
Either digoxin, Ca channel blockers or  blockers
should be administered for control of heart rates
because these drugs can suppress atrioventricular
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nodal conduction. The DAAF study revealed that
digoxin possessed weak eﬀect for deﬁbrillation but
signiﬁcantly reduced heart rate36) (Figure 9). The
result of a comparison of the heart rate reducing
eﬀects in the patients with heart failure between
diltiazem and verapamil as the Ca channel blockers,
and placebo with use of Holter electrocardiogram,37)
the respective heart rates were 88 14 beat/min.
with placebo, 76 13 beats/min. with diltiazem
270mg/day (P < 0:001) and 80 11 beats/min.
with verapamil 240mg/day (P < 0:01), suggesting
that both Ca channel blockers exhibited equipotent
First attach, alcohol, after cardiac operation, hyperthyroidismyesNo treatment
Juvenile, exercise inducedyesβ blocker
others
Antiarrhythmic agents
Cardiac function
normal Mildly impaired, 
Hypertrophic cardiomyopathy
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Figure 8 Prevention of atrial ﬁbrillation according to the Japanese guidelines for atrial ﬁbrillation.
(Reproduced with permission from reference 20).
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Figure 9 Digitalis in acute atrial ﬁbrillation (DAAF) trial.
Left panel shows time course of restoration to sinus rhythm, and right panel shows eﬃcacy for heart rate during atrial ﬁbrillation.
(Represented with permission from reference 36)
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suppression of conduction through atrioventricular
node and improvement in exercise tolerance. 
blockers also inhibit atrioventricular nodal conduc-
tion. Particularly,  blockers are recommended to be
used in the patients who show elevation of heart
rates during the daytime. In the ICU, intravenous
administration of these drugs is usually used to
improve subjective symptoms at early stages. Intra-
venous injection of digoxin provides the simplest
application in the clinical situation because proce-
dures consist of dissolving digoxin 0.25mg in one
syringe either in 20ml of saline or 5% glucose
solution, followed by intravenous bolus injection for
several minutes. Alternatively, there is another
method comprising addition of one syringe of
digoxin to 100ml of intravenous solution and
subsequent administration of the solution within
15–30 minutes. Given the fact that amiodarone and
bepridil for deﬁbrillation in the patients with lower
cardiac functions lead to time-course decrease in
heart rates during atrial ﬁbrillation, it is conceivable
that these drugs should be used with due care paid to
adverse reactions. However, anticoagulant therapy
should be attempted even in the patients who are
classiﬁed to be treated with heart rate controls.
Thromboembolism and cerebral in-
farction
Although atrial ﬁbrillation is not a lethal arrhyth-
mia, it cannot be clinically neglected from the major
cause of cardiogenic cerebral infarction. The patients
with atrial ﬁbrillation are characterized with lowered
blood ﬂow both in the left atrium and the left atrial
appendage, resulting in retention of blood ﬂow in the
left atrium and appendage, thereby causing ﬁbrin
thrombus. Medication with anticoagulants is eﬀec-
tive in prevention of such thrombus formation.
According to the large-scale clinical studies in
Europe and America which compared eﬃcacies on
prevention of cerebral infarction in the patients with
atrial ﬁbrillation between warfarin as anticoagulant
and aspirin as antiplatelet agent, warfarin was
superior to aspirin.38) Although aspirin is eﬀective,
warfarin as an anticoagulant exerts higher eﬃcacy in
prevention of thromboembolism. The eﬀect of
warfarin appears approximately 4 to 5 days after
initiation of oral administration. When prompt
eﬃcacy is expected, administration of heparin as
anticoagulant is required.
The dosages of warfarin should be independently
titrated according to individual patients; accordingly,
its dosage is adjusted based on either thrombotest or
prothrombin time. The eﬃcacy of warfarin is
represented as international normalized ratio (INR).
In SPAF III a large-scale clinical study in Europe
and America,39) comparison was made between the
warfarin group whose INR was adjusted to the levels
of 2.0 to 3.0 and the combination therapy group in
which warfarin at the ﬁxed initial dose (1.2 to 1.5 as
the INR) and aspirin at the dose of 325mg were
concomitantly administered. The results obtained in
this study revealed lower prevalence of embolism in
the group with higher INR levels, leading to ﬁrm
contention that warfarin is not eﬀective unless INR
was more than 2.0. On the other hand, taking into
account the ﬁndings that most of patients with
hemorrhagic complications due to warfarin admin-
istration in EAFT40) were found to show INR at
levels of more than 5.0, care should be exercised to
avoid raising the INR level to more than 5.0.
Therefore, it has been perceived in Europe and
America that warfarin administration at doses of INR
2.0 to 3.0 is eﬀective in prevention of cerebral
embolism.
Appropriate patients indicated for an-
ticoagulant therapy
There are several issues as to whether anticoagu-
lants should be administered to all the patients with
atrial ﬁbrillation. According to the results obtained
by large-scale clinical studies, in principle, warfarin
administration is recommended to all patients of
more than 65 years of age to prevent embolism
secondary to non valvular atrial ﬁbrillation whereas
even in the patients of less than 65 years of age,
warfarin medication is advocated if they have a past
history of hypertension, diabetes mellitus, embolism
or temporary cerebral ischemia attacks, as well as
underlying heart diseases. It is recommended to
administer aspirin 325mg to the patients who are
inappropriate to be medicated with or contraindicat-
ed to warfarin. However, these ﬁndings were
obtained in European and American subjects, indi-
cating that we must separately investigate to which
levels warfarin dosage should be titrated for treat-
ment of a Japanese population characterized by a
trend toward a greater susceptibility to hemorrhage.
We have a concern about long-term administration
of aspirin to Japanese people suﬀering from gastro-
intestinal disorders. Clinical study by Yamaguchi41)
on prevention of secondary cerebral infarction
evidenced that warfarin at the INR levels of 1.5 to
2.1 was found eﬀective in prevention of cerebral
infarction, whereby we think that INR should be
adjusted to 1.5 to 2.1 for Japanese patients.
In addition, it is also recommended that upon
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deﬁbrillation of paroxysmal atrial ﬁbrillation lasting
for more than 3 days and persistent atrial ﬁbrillation
responsive to deﬁbrillation, warfarin is administered
3 weeks prior to deﬁbrillation, followed by addi-
tional warfarin medication for 4 weeks after restora-
tion to sinus rhythm. However, there is a concern
about the possibility that atrial remodeling (i.e.
atrium becoming vulnerable to onset of atrial
ﬁbrillation) might progress in parallel with admin-
istration of warfarin for as long as 3 weeks before
deﬁbrillation, thereby lending some support to the
suggestion that prompt deﬁbrillation should be
performed. Under these situations, it is conceivable
that deﬁbrillation with heparin as an anticoagulant
for intravenous use and simultaneous medication
with warfarin are really warranted.
In this connection, transesophageal echocardiog-
raphy is also recommended to achieve early deﬁb-
rillation. Even in the patients with long-lasting atrial
ﬁbrillation, early deﬁbrillation is feasible unless
transesophageal echocardiography reveals spontane-
ous echo contrast or thrombus clot either in left
atrium or left atrial appendage. In reality, there is a
possibility that atrial stunning after deﬁbrillation
contributes to occurrence of thrombus clot after
deﬁbrillation; therefore, for prevention of these
secondary complications, anticoagulant therapy
should be strictly conducted after deﬁbrillation.
Naturally, if transesophageal echocardiography de-
tects thrombus, deﬁbrillation should be discontinued
and we must wait until thrombus clot is dissolved by
warfarin treatment. As is obvious from the above,
the advantage of performing transesophageal echo-
cardiography exists only on conﬁrmation of absence
of thrombus clot either in left atrium or left atrial
appendage just before deﬁbrillation. One must keep
in mind that absence of thrombus clot does not
necessarily guarantee successful prevention of em-
bolism after deﬁbrillation.
Conclusions
This article deals with pharmacological treatment
for atrial ﬁbrillation according to pharmacological
deﬁbrillation, maintenance of sinus rhythm, heart
rate control and antiembolism therapy. In addition,
ACE inhibitors to prevent atrial remodeling or ARB
are currently used in clinical situations. One should
select appropriate drugs for pharmacological treat-
ment of atrial ﬁbrillation based on deﬁnite objec-
tives.
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